Cargando…
Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress
The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer’s disease (AD), whereas they tend to occur early on in the case of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413102/ https://www.ncbi.nlm.nih.gov/pubmed/32848775 http://dx.doi.org/10.3389/fphar.2020.01168 |
_version_ | 1783568738506768384 |
---|---|
author | Magierski, Radoslaw Sobow, Tomasz Schwertner, Emilia Religa, Dorota |
author_facet | Magierski, Radoslaw Sobow, Tomasz Schwertner, Emilia Religa, Dorota |
author_sort | Magierski, Radoslaw |
collection | PubMed |
description | The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer’s disease (AD), whereas they tend to occur early on in the case of its behavioral variant frontotemporal dementia or dementia with Lewy bodies and are essential for diagnosis. BPSD treatment consists of non-pharmacological as well as pharmacological interventions, with non-pharmacological interactions being suggested as first-line treatment. Agitation, psychotic features, apathy, depression, and anxiety may not respond to acetylcholinesterase inhibitors or memantine in AD cases; therefore, antipsychotics, antidepressants, sedative drugs or anxiolytics, and antiepileptic drugs are typically prescribed. However, such management of BPSD can be complicated by hypersensitivity to antipsychotic drugs, as observed in DLB, and a lack of effective pro-cognitive treatment in the case of frontotemporal dementia. The present paper reviews current knowledge of the management of BPSD and its limitations and discusses on-going clinical trials and future therapeutic options. |
format | Online Article Text |
id | pubmed-7413102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74131022020-08-25 Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress Magierski, Radoslaw Sobow, Tomasz Schwertner, Emilia Religa, Dorota Front Pharmacol Pharmacology The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer’s disease (AD), whereas they tend to occur early on in the case of its behavioral variant frontotemporal dementia or dementia with Lewy bodies and are essential for diagnosis. BPSD treatment consists of non-pharmacological as well as pharmacological interventions, with non-pharmacological interactions being suggested as first-line treatment. Agitation, psychotic features, apathy, depression, and anxiety may not respond to acetylcholinesterase inhibitors or memantine in AD cases; therefore, antipsychotics, antidepressants, sedative drugs or anxiolytics, and antiepileptic drugs are typically prescribed. However, such management of BPSD can be complicated by hypersensitivity to antipsychotic drugs, as observed in DLB, and a lack of effective pro-cognitive treatment in the case of frontotemporal dementia. The present paper reviews current knowledge of the management of BPSD and its limitations and discusses on-going clinical trials and future therapeutic options. Frontiers Media S.A. 2020-07-31 /pmc/articles/PMC7413102/ /pubmed/32848775 http://dx.doi.org/10.3389/fphar.2020.01168 Text en Copyright © 2020 Magierski, Sobow, Schwertner and Religa http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Magierski, Radoslaw Sobow, Tomasz Schwertner, Emilia Religa, Dorota Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title | Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title_full | Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title_fullStr | Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title_full_unstemmed | Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title_short | Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress |
title_sort | pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413102/ https://www.ncbi.nlm.nih.gov/pubmed/32848775 http://dx.doi.org/10.3389/fphar.2020.01168 |
work_keys_str_mv | AT magierskiradoslaw pharmacotherapyofbehavioralandpsychologicalsymptomsofdementiastateoftheartandfutureprogress AT sobowtomasz pharmacotherapyofbehavioralandpsychologicalsymptomsofdementiastateoftheartandfutureprogress AT schwertneremilia pharmacotherapyofbehavioralandpsychologicalsymptomsofdementiastateoftheartandfutureprogress AT religadorota pharmacotherapyofbehavioralandpsychologicalsymptomsofdementiastateoftheartandfutureprogress |